YUMMER1.7 is an immune competent melanoma model, relatively resistant to immunotherapy with anti-PD1 + anti-CTLA4 as the majority of YUMMER1.7-bearing mice have tumor progression on anti-PD1 monotherapy and do not reject their tumors [19]. This evidence concerns the gene CTLA4 and melanoma.